马云捐1亿人币支持研发新肺炎疫苗
马云公益基金会昨日(29日)宣布,将捐赠1亿元人民币(下同)支持冠状病毒的疫苗研发。其中,捐赠中国科学院和中国工程院各2,000万元,用於其所属专业研究机构当前病毒疫苗专项研发,其余资金将用於支持国内外各顶尖科研机构和科研人员合作展开对新型冠状病毒的预防治疗工作。
马云公益基金会表示,尽管科研人员已经争分夺秒、全力以赴,但疫苗从研究到最终投入使用绝非一朝一夕的易事,希望在疫苗问世之前疫情就完全得到控制,但人类与病毒的斗争是一条漫长的道路,需要更多的耐心和累积,也需要更多的信心与希望。
同时,阿里巴巴(09988.HK)将为公共科研机构免费开放本次病毒疫苗和新药研发所需的一切AI(人工智能)算力。阿里早前亦设立了10亿元医疗物资供应专项基金。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.